Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients

Experimental Hematology

Volumn 43, Issue 12, 2015, Pages 1015-1018.e1

  Caocci, Giovanni ^a   Martino, Bruno ^b   Greco, Marianna ^a   Abruzzese, Elisabetta ^c   Trawinska, Malgorzata Monika ^c   Lai, Sara ^a   Ragatzu, Paola ^a   Galimberti, Sara ^d   Baratè, Claudia ^d   Mulas, Olga ^a   Labate, Claudia ^b   Littera, Roberto ^a   Carcassi, Carlo ^a   Passerini, Carlo Gambacorti ^e   La Nasa, Giorgio ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMATINIB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; KIR3DL1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HLA TYPING; HOMOZYGOSITY; HUMAN; KIR3DL GENE; KIR3DS1 GENE; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; REMISSION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTORS, KIR3DL1; RECEPTORS, KIR3DS1; SURVIVAL RATE;

EID: 84944128420     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.08.004     Document Type: Article

References (16)

1. Mahon F.X., Réa D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1035.
2. Ross D.M., Branford S., Seymour J.F., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013, 122:515-522.
3. Rousselot P., Charbonnier A., Cony-Makhoul P., et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014, 32:424-430.
4. Goldman J., Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk Lymphoma 2006, 47:1-7.
5. Ilander M., Hekim C., Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014, 9:17-23.
6. Middleton D., Diler A.S., Meenagh A., Sleator C., Gourraud P.A. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukemia. Tissue Antigens 2009, 73:553-560.
7. Marin D., Gabriel I.H., Ahmad S., et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012, 26:296-302.
8. Kreutzman A., Jaatinen T., Greco D., et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol 2012, 40:906-913.
9. Mizoguchi I., Yoshimoto T., Katagiri S., et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013, 104:1146-1153.
10. Rea D., Dulphy N., Henry G., et al. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from Immunostim, on behalf of STIM investigators. Blood 2013, 122:856.
11. Ilander M.M., Olsson-Strömberg U., Lähteenmäki H., et al. Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-Cells. Blood 2014, 124:812.
12. Purdy A.K., Campbell K.S. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009, 8:2211-2220.
13. Hsu K.C., Chida S., Geraghty D.E., Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002, 190:40-52.
14. La Nasa G., Caocci G., Littera R., et al. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol 2013, 41:424-431.
15. Mori S., Vagge E., le Coutre P., et al. The risk of relapse in CML patients who discontinued imatinib can be predicted based on patients age and the results of dPCR analysis. Blood 2014, 124:813.
16. Parham P., Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013, 13:133-144.